Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have received a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $10.80.

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Regulus Therapeutics in a research report on Monday, November 11th.

Regulus Therapeutics Price Performance

Shares of RGLS opened at $1.32 on Thursday. Regulus Therapeutics has a one year low of $0.83 and a one year high of $3.79. The firm has a market capitalization of $86.46 million, a P/E ratio of -1.23 and a beta of 1.58. The business has a fifty day moving average of $1.44 and a 200 day moving average of $1.53.

Regulus Therapeutics (NASDAQ:RGLS) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). Analysts expect that Regulus Therapeutics will post -0.88 EPS for the current fiscal year.

Insider Activity

In other news, CEO Joseph P. Hagan sold 115,290 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $145,265.40. Following the transaction, the chief executive officer now directly owns 222,572 shares in the company, valued at $280,440.72. The trade was a 34.12 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Christopher Ray Aker sold 38,547 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now owns 54,634 shares in the company, valued at $68,838.84. This represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 223,998 shares of company stock worth $282,237 over the last ninety days. Corporate insiders own 4.35% of the company’s stock.

Institutional Investors Weigh In On Regulus Therapeutics

Several large investors have recently added to or reduced their stakes in RGLS. NEA Management Company LLC bought a new stake in Regulus Therapeutics during the third quarter worth approximately $10,154,000. Point72 Asset Management L.P. bought a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $1,403,000. The Manufacturers Life Insurance Company bought a new position in shares of Regulus Therapeutics during the third quarter valued at approximately $204,000. Tyche Wealth Partners LLC grew its stake in shares of Regulus Therapeutics by 920.6% during the third quarter. Tyche Wealth Partners LLC now owns 106,089 shares of the biopharmaceutical company’s stock valued at $167,000 after buying an additional 95,694 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Regulus Therapeutics by 285.2% during the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock valued at $132,000 after buying an additional 62,549 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.